SEC Comment Letter for Brickell Biotech, Inc. (FRTX) (CIK 0000819050) — Mar 12, 2021
Brickell Biotech, Inc. (FRTX) (CIK 0000819050)
Date: March 12, 2021 · CIK: 0000819050 · Accession: 0000000000-21-002998
AI Filing Summary & Sentiment
File numbers found in text: 333-254037
Letter
United States securities and exchange commission logo March 12, 2021 Robert Brown Chief Executive Officer Brickell Biotech, Inc. 5777 Central Avenue, Suite 102 Boulder, CO 80301 Re:Brickell Biotech, Inc. Registration Statement on Form S-3 Filed March 9, 2021 File No. 333-254037 Dear Mr. Brown: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jonathan R. Zimmerman, Esq.
Show Raw Text
United States securities and exchange commission logo
March 12, 2021
Robert Brown
Chief Executive Officer
Brickell Biotech, Inc.
5777 Central Avenue, Suite 102
Boulder, CO 80301
Re:Brickell Biotech, Inc.
Registration Statement on Form S-3
Filed March 9, 2021
File No. 333-254037
Dear Mr. Brown:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jonathan R. Zimmerman, Esq.